Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells

Dong,Zhongyun; Meller,Jaroslaw; Succop,Paul; Wang,Jiang; Wikenheiser-Brokamp,Kathryn; Starnes,Sandra; Lu,Shan

doi:10.3892/ijo.2014.2486

Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells

Authors:
- Zhongyun Dong
- Jaroslaw Meller
- Paul Succop
- Jiang Wang
- Kathryn Wikenheiser-Brokamp
- Sandra Starnes
- Shan Lu
View Affiliations

Affiliations: Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45237, USA, Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH 45237, USA, Department of Pathology, University of Cincinnati College of Medicine, Cincinnati, OH 45237, USA, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH 45237, USA
Published online on: June 10, 2014 https://doi.org/10.3892/ijo.2014.2486
Pages: 978-984
Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of cancer death worldwide. There is an urgent need for early diagnostic tools and novel therapies in order to increase lung cancer survival. Secretory phospholipase A2 group IIa (sPLA2-IIa) is involved in inflammation, tumorigenesis and metastasis. We were the first to uncover that cancer cells secrete sPLA2‑IIa. sPLA2‑IIa is overexpressed in almost all specimens of human lung cancers examined and is significantly elevated in the plasma of lung cancer patients. High levels of plasma sPLA2-IIa are significantly associated with advanced stage and decreased overall cancer survival. In this study, we further showed that elevated HER/HER2‑PI3K-Akt-NF-κB signaling contributes to sPLA2-IIa overexpression in lung cancer cells. sPLA2-IIa in turn phosphorylates and activates HER2 and HER3 in a time- and dose‑dependent manner in lung cancer cells. The structure and sequence‑based docking analysis revealed that sPLA2-IIa β hairpin shares structural similarity with the corresponding EGF hairpin. sPLA2-IIa forms an extensive interface with EGFR and brings the two lobes of EGFR into an active conformation. sPLA2-IIa also enhances the NF-κB promoter activity. Anti-sPLA2-IIa antibody, but not the small molecule sPLA2-IIa inhibitor LY315920, significantly inhibits sPLA2‑IIa-induced activation of NF-κB promoter. Our findings support the notion that sPLA2-IIa functions as a ligand for the EGFR family of receptors leading to an elevated HER/HER2-elicited signaling. Plasma sPLA2-IIa can potentially serve as lung cancer biomarker and sPLA2‑IIa is a potential therapeutic target against lung cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2	Peters S, Adjei AA, Gridelli C, Reck M, Kerr K and Felip E: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23(Suppl 7): vii56–vii64. 2012. View Article : Google Scholar : PubMed/NCBI
3	Gridelli C, Ardizzoni A, Douillard JY, et al: Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer. 68:319–331. 2010. View Article : Google Scholar
4	Pisters KM, Evans WK, Azzoli CG, et al: Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I–IIIA resectable non small-cell lung cancer guideline. J Clin Oncol. 25:5506–5518. 2007.PubMed/NCBI
5	Goffin J, Lacchetti C, Ellis PM, Ung YC and Evans WK: First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol. 5:260–274. 2010. View Article : Google Scholar : PubMed/NCBI
6	Cataldo VD, Gibbons DL, Perez-Soler R and Quintas-Cardama A: Treatment of non-small-cell lung cancer with erlotinib or gefitinib. New Engl J Med. 364:947–955. 2011. View Article : Google Scholar : PubMed/NCBI
7	Gazdar AF: Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev. 29:37–48. 2010. View Article : Google Scholar : PubMed/NCBI
8	Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer - molecular and clinical predictors of outcome. New Engl J Med. 353:133–144. 2005. View Article : Google Scholar : PubMed/NCBI
9	Munoz M, Henderson M, Haber M and Norris M: Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life. 59:752–757. 2007. View Article : Google Scholar : PubMed/NCBI
10	Modok S, Mellor HR and Callaghan R: Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol. 6:350–354. 2006. View Article : Google Scholar : PubMed/NCBI
11	Detterbeck FC, Boffa DJ and Tanoue LT: The new lung cancer staging system. Chest. 136:260–271. 2009. View Article : Google Scholar
12	Henschke CI, McCauley DI, Yankelevitz DF, et al: Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 354:99–105. 1999. View Article : Google Scholar : PubMed/NCBI
13	Wahidi MM, Govert JA, Goudar RK, Gould MK and McCrory DC: Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 132:94S–107S. 2007. View Article : Google Scholar
14	Starnes SL, Reed MF, Meyer CA, et al: Lung cancer screening with low-dose CT in an area endemic for Histoplasma Capsulatum: minimizing invasive procedures for benign nodules. J Thorac Cardiovasc Surg. 141:688–693. 2011. View Article : Google Scholar : PubMed/NCBI
15	Team TNLSTR. Reduced lung-cancer mortality with low-dose computed tomographic screening. New Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
16	Lederle FA and Niewoehner DE: Lung cancer surgery. A critical review of the evidence. Arch Intern Med. 154:2397–2400. 1994. View Article : Google Scholar : PubMed/NCBI
17	Cummings BS: Phospholipase A2 as targets for anti-cancer drugs. Biochem Pharmacol. 74:949–959. 2007. View Article : Google Scholar : PubMed/NCBI
18	Lambeau G and Lazdunski M: Receptors for a growing family of secreted phospholipases A2. Trends Pharmacol Sci. 20:162–170. 1999. View Article : Google Scholar : PubMed/NCBI
19	Antonio V, Brouillet A, Janvier B, et al: Transcriptional regulation of the rat type IIA phospholipase A2 gene by cAMP and interleukin-1beta in vascular smooth muscle cells: interplay of the CCAAT/enhancer binding protein (C/EBP), nuclear factor-kappaB and Ets transcription factors. Biochem J. 368:415–424. 2002. View Article : Google Scholar
20	Dong Z, Liu Y, Scott KF, et al: Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. Carcinogenesis. 31:1948–1955. 2010. View Article : Google Scholar : PubMed/NCBI
21	Triggiani M, Granata F, Giannattasio G and Marone G: Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. Journal Allergy Clin Immunol. 116:1000–1006. 2005. View Article : Google Scholar : PubMed/NCBI
22	Meyer AM, Dwyer-Nield LD, Hurteau GJ, et al: Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis. 25:1517–1524. 2004. View Article : Google Scholar : PubMed/NCBI
23	Kupert E, Anderson M, Liu Y, et al: Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules. BMC Cancer. 11:5132011. View Article : Google Scholar : PubMed/NCBI
24	Lu S, Tsai SY and Tsai MJ: Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology. 140:5054–5059. 1999.PubMed/NCBI
25	Oleksowicz L, Liu Y, Bracken RB, et al: Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and potential plasma biomarker for poor prognosis of prostate cancer. Prostate. 72:1140–1149. 2012. View Article : Google Scholar : PubMed/NCBI
26	Schulze WX, Deng L and Mann M: Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol. 1:2005.00082005. View Article : Google Scholar
27	Hsieh AC and Moasser MM: Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 97:453–457. 2007. View Article : Google Scholar : PubMed/NCBI
28	Lovly CM and Carbone DP: Lung cancer in 2010: One size does not fit all. Nat Rev Clin Oncol. 8:68–70. 2011. View Article : Google Scholar : PubMed/NCBI
29	Davies AM, Lara PN Jr, Mack PC and Gandara DR: Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res. 13:s4647–s4651. 2007. View Article : Google Scholar : PubMed/NCBI
30	Engelman JA and Cantley LC: The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 12:4372s–4376s. 2006. View Article : Google Scholar
31	Tas SW, Vervoordeldonk MJ and Tak PP: Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer. Curr Gene Ther. 9:160–170. 2009. View Article : Google Scholar : PubMed/NCBI
32	Escobar M, Velez M, Belalcazar A, Santos ES and Raez LE: The role of proteasome inhibition in nonsmall cell lung cancer. J Biomed Biotechnol. 2011:8065062011. View Article : Google Scholar : PubMed/NCBI
33	Sved P, Scott KF, McLeod D, et al: Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res. 64:6934–6940. 2004. View Article : Google Scholar : PubMed/NCBI
34	Patel MI, Singh J, Niknami M, et al: Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer. Clin Cancer Res. 14:8070–8079. 2008. View Article : Google Scholar : PubMed/NCBI
35	Belinsky GS, Rajan TV, Saria EA, Giardina C and Rosenberg DW: Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth. Mol Carcinog. 46:106–116. 2007. View Article : Google Scholar : PubMed/NCBI
36	Mulherkar R, Kirtane BM, Ramchandani A, Mansukhani NP, Kannan S and Naresh KN: Expression of enhancing factor/phospholipase A2 in skin results in abnormal epidermis and increased sensitivity to chemical carcinogenesis. Oncogene. 22:1936–1944. 2003. View Article : Google Scholar
37	Hernandez M, Martin R, Garcia-Cubillas MD, Maeso-Hernandez P and Nieto ML: Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link. Neuro Oncol. 12:1014–1023. 2010. View Article : Google Scholar : PubMed/NCBI
38	Martin R, Hernandez M, Ibeas E, et al: Secreted phospholipase A2-IIA modulates key regulators of proliferation on astrocytoma cells. J Neurochem. 111:988–999. 2009. View Article : Google Scholar : PubMed/NCBI
39	Narayanan BA, Narayanan NK, Pittman B and Reddy BS: Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res. 10:7727–7737. 2004. View Article : Google Scholar
40	Kobayashi N, Barnard RJ, Henning SM, et al: Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res. 12:4662–4670. 2006. View Article : Google Scholar
41	Dong Z, Liu Y, Levin L, Oleksowicz L, Wang J and Lu S: Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer. Oncol Rep. 25:1511–1516. 2011.
42	Granata F, Frattini A, Loffredo S, et al: Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol. 184:5232–5241. 2010. View Article : Google Scholar
43	Baek SH, Lim JH, Park DW, et al: Group IIA secretory phospholipase A(2) stimulates inducible nitric oxide synthase expression via ERK and NF-kappaB in macrophages. Eur J Immunol. 31:2709–2717. 2001. View Article : Google Scholar : PubMed/NCBI
44	Park DW, Kim JR, Kim SY, et al: Akt as a mediator of secretory phospholipase A2 receptor-involved inducible nitric oxide synthase expression. J Immunol. 170:2093–2099. 2003. View Article : Google Scholar : PubMed/NCBI
45	Ibeas E, Fuentes L, Martin R, Hernandez M and Nieto ML: Inflammatory protein sPLA(2)-IIA abrogates TNFalpha-induced apoptosis in human astroglioma cells: Crucial role of ERK. Biochim Biophys Acta. 1793:1837–1847. 2009. View Article : Google Scholar
46	Scott KF, Sajinovic M, Hein J, et al: Emerging roles for phospholipase A2 enzymes in cancer. Biochimie. 92:601–610. 2010. View Article : Google Scholar : PubMed/NCBI
47	Valentin E and Lambeau G: Increasing molecular diversity of secreted phospholipases A(2) and their receptors and binding proteins. Biochim Biophys Acta. 1488:59–70. 2000. View Article : Google Scholar : PubMed/NCBI
48	Hernandez M, Burillo SL, Crespo MS and Nieto ML: Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1. J Biol Chem. 273:606–612. 1998. View Article : Google Scholar
49	Yu JA, Mauchley D, Li H, et al: Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo. J Thorac Cardiovasc Surg. 144:1185–1191. 2012. View Article : Google Scholar : PubMed/NCBI